Takahito Doi

739 total citations
24 papers, 431 citations indexed

About

Takahito Doi is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Takahito Doi has authored 24 papers receiving a total of 431 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Surgery, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Takahito Doi's work include Lipoproteins and Cardiovascular Health (14 papers), Cancer, Lipids, and Metabolism (7 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers). Takahito Doi is often cited by papers focused on Lipoproteins and Cardiovascular Health (14 papers), Cancer, Lipids, and Metabolism (7 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers). Takahito Doi collaborates with scholars based in Japan, Denmark and India. Takahito Doi's co-authors include Børge G. Nordestgaard, Anne Langsted, Teruo Noguchi, Satoshi Yasuda, Yu Kataoka, Kunihiro Nishimura, Yoshio Tahara, Takahiro Nakashima, Yasuhide Asaumi and Kazuhiro Nakao and has published in prestigious journals such as Journal of the American College of Cardiology, European Heart Journal and Arteriosclerosis Thrombosis and Vascular Biology.

In The Last Decade

Takahito Doi

22 papers receiving 421 citations

Peers

Takahito Doi
Honin Kanaya Japan
Ryo Kameda Japan
Sandra N. Verhagen Netherlands
Yoshio Taketani Japan
S. J. Leslie United States
Ananya Hooda United States
Craig Balog United States
Kazuma Oyama Japan
Sida Jia China
Hirofumi Kawamata Japan
Honin Kanaya Japan
Takahito Doi
Citations per year, relative to Takahito Doi Takahito Doi (= 1×) peers Honin Kanaya

Countries citing papers authored by Takahito Doi

Since Specialization
Citations

This map shows the geographic impact of Takahito Doi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takahito Doi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takahito Doi more than expected).

Fields of papers citing papers by Takahito Doi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takahito Doi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takahito Doi. The network helps show where Takahito Doi may publish in the future.

Co-authorship network of co-authors of Takahito Doi

This figure shows the co-authorship network connecting the top 25 collaborators of Takahito Doi. A scholar is included among the top collaborators of Takahito Doi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takahito Doi. Takahito Doi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Doi, Takahito, Anne Langsted, & Børge G. Nordestgaard. (2025). Remnant Cholesterol: Should it be a Target for Prevention of ASCVD?. Current Atherosclerosis Reports. 27(1). 44–44. 2 indexed citations
2.
3.
Elías-López, Daniel, Camilla J. Kobylecki, Signe Vedel‐Krogh, Takahito Doi, & Børge G. Nordestgaard. (2025). Association of low-grade inflammation and elevated remnant cholesterol with risk of ASCVD and mortality in impaired renal function. Atherosclerosis. 406. 119241–119241. 2 indexed citations
4.
Doi, Takahito, Anne Langsted, & Børge G. Nordestgaard. (2024). Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial. Atherosclerosis. 393. 117556–117556. 8 indexed citations
5.
Kataoka, Yu, Mika Hori, Masatsune Ogura, et al.. (2024). Asymptomatic Intracranial Artery Stenosis/Occlusion in Heterozygous Familial Hypercholesterolemia: Its Frequency and Implications for Cerebrovascular and Cardiovascular Events. Journal of the American Heart Association. 13(15). e033972–e033972.
6.
7.
Doi, Takahito, Anne Langsted, & Børge G. Nordestgaard. (2023). Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality. Atherosclerosis. 379. 117141–117141. 36 indexed citations
8.
Doi, Takahito, Børge G. Nordestgaard, & Anne Langsted. (2023). Can remnant cholesterol (triglyceride-rich lipoproteins) reclassify estimated risk of atherosclerotic cardiovascular disease?. Current Opinion in Endocrinology Diabetes and Obesity. 30(2). 128–135. 13 indexed citations
9.
Doi, Takahito, Anne Langsted, & Børge G. Nordestgaard. (2023). Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans. Journal of Atherosclerosis and Thrombosis. 30(11). 1525–1546. 16 indexed citations
10.
Doi, Takahito, Anne Langsted, & Børge G. Nordestgaard. (2022). Elevated Remnant Cholesterol Reclassifies Risk of Ischemic Heart Disease and Myocardial Infarction. Journal of the American College of Cardiology. 79(24). 2383–2397. 71 indexed citations
11.
Kataoka, Yu, et al.. (2022). Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels. Journal of the American Heart Association. 11(16). e025232–e025232. 6 indexed citations
12.
Kataoka, Yu, Mika Hori, Masatsune Ogura, et al.. (2021). Substantially Elevated Atherosclerotic Risks in Japanese Severe Familial Hypercholesterolemia Defined by the International Atherosclerosis Society. JACC Asia. 1(2). 245–255. 7 indexed citations
13.
14.
Doi, Takahito, Mika Hori, Mariko Harada‐Shiba, et al.. (2021). Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia. Journal of the American Heart Association. 10(4). e018263–e018263. 15 indexed citations
15.
Kataoka, Yu, Fumiyuki Otsuka, Yuriko Nakaoku, et al.. (2020). Cardiac outcomes in patients with acute coronary syndrome attributable to calcified nodule. Atherosclerosis. 318. 70–75. 55 indexed citations
16.
Kataoka, Yu, Soshiro Ogata, Kunihiro Nishimura, et al.. (2020). Diminished response to statins predicts the occurrence of heart failure after acute myocardial infarction. Cardiovascular Diagnosis and Therapy. 10(4). 705–716. 5 indexed citations
17.
Kataoka, Yu, Mika Hori, Masatsune Ogura, et al.. (2020). Lp (a) >50 mg/dl predicts atherosclerotic cardiovascular events in patients with heterozygous familial hypercholesterolemia who achieved LDL-C <2.6 mmol/l. European Heart Journal. 41(Supplement_2). 1 indexed citations
18.
Doi, Takahito, Osami Kawarada, Taka‐aki Matsuyama, et al.. (2019). Successful use of last-option infrapopliteal rotational atherectomy despite microembolisation. PubMed. 5(1). 53–56. 1 indexed citations
19.
Doi, Takahito, et al.. (2018). Iliac artery stent fracture associated with hip joint flexion. Cardiovascular Intervention and Therapeutics. 34(2). 180–181. 1 indexed citations
20.
Doi, Takahito, Yu Kataoka, Teruo Noguchi, et al.. (2017). Coronary Artery Ectasia Predicts Future Cardiac Events in Patients With Acute Myocardial Infarction. Arteriosclerosis Thrombosis and Vascular Biology. 37(12). 2350–2355. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Honin Kanaya Breakdown of academic impact, for papers by Ryo Kameda Breakdown of academic impact, for papers by Sandra N. Verhagen Breakdown of academic impact, for papers by Yoshio Taketani Breakdown of academic impact, for papers by S. J. Leslie Breakdown of academic impact, for papers by Ananya Hooda Breakdown of academic impact, for papers by Craig Balog Breakdown of academic impact, for papers by Kazuma Oyama Breakdown of academic impact, for papers by Sida Jia Breakdown of academic impact, for papers by Hirofumi Kawamata
Rankless by CCL
2026